Nasdaq News

(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK, 4502.T) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis.

(RTTNews) - Roche Holding AG (RHHBY), a healthcare company, announced two regulatory developments, with the U.S. FDA accepting its New Drug Application (NDA) for Fenebrutinib in relapsing multiple sclerosis and primary progressive multiple sclerosis under Priority Review.

(RTTNews) - AbbVie (ABBV) announced positive interim results from the Phase 2 APEX Part B dose-regimen-finding Study of zumilokibart in adult patients with moderate to severe atopic dermatitis, supporting further development of the investigational therapy.

Key PointsOracle's rising bond yields have raised concerns about how the AI build-out will be financed moving forward.

(RTTNews) - A strong positive sentiment is expected to prevail in European stock markets on Wednesday amidst a sharp decline in Fed rate hike expectations. The decline in crude oil prices, the easing in bond yields and the dollar's retreat are also expected to bolster sentiment.

(RTTNews) - Swiss drug major Roche Holding AG (RHHBY, RO.SW, ROG.SW) announced Wednesday the launch of newborn screening test for three severe genetic conditions, such as Spinal Muscular Atrophy or SMA, Severe Combined Immunodeficiency Disease or SCID, and Sickle Cell Disease or

(RTTNews) - TomTom N.V. (TOM2.AS), a location technology specialist, Wednesday announced its expanded collaboration with major global technology company, Microsoft (MSFT), bringing TomTom's location intelligence to AI agents built on Microsoft Fabric and Microsoft Foundry through

(RTTNews) - AbbVie (ABBV) reported positive results from the Phase 2 APEX Part B study of zumilokibart, in adults with moderate to severe atopic dermatitis.

(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK,4502.T) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis.

(RTTNews) - Galderma (GALD) announced new three-year results from the ARCADIA long-term extension study showing that Nemluvio (nemolizumab) was associated with sustained improvements in patients with moderate-to-severe atopic dermatitis.

(RTTNews) - Galderma (GALD) reported new three-year data from the ARCADIA long-term extension study showing that Nemluvio (nemolizumab) was associated with sustained improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-

(RTTNews) - Dyne Therapeutics (DYNE) announced on Tuesday additional one-year clinical data from the Phase 1/2 ACHIEVE trial of investigational Z-basivarsen showing sustained functional improvements across multiple measures in patients with myotonic dystrophy type 1.

(RTTNews) - Genentech, affiliated to Swiss drug major Roche Holding AG (RHHBY, RO.SW, ROG.SW) announced Wednesday that the U.S. Food and Drug Administration has accepted its New Drug Application or NDA under priority review for fenebrutinib in both relapsing and primary progressi

Key PointsOracle spent $28.5 billion on capital expenditures last quarter, far more than its $19.3 billion in revenue.

(RTTNews) - The Walt Disney Company (DIS) is eliminating hundreds of jobs in its human resources and technology functions, Reuters reported, citing a source familiar with the matter.

(RTTNews) - Huntington Ingalls Industries, Inc. (HII), a military shipbuilder, Tuesday announced that its Newport News Shipbuilding division has secured a $5.09 billion contract for the refueling and complex overhaul or RCOH of nuclear-powered aircraft carrier USS Harry S. Truman

(RTTNews) - DBV Technologies (DBVT) announced that it has submitted a Biologics License Application to the U.S. FDA for the VIASKIN Peanut Patch in children aged 4 through 7 years with peanut allergy. The company has requested Priority Review of the application.

(RTTNews) - Larimar Therapeutics, Inc. (LRMR), a clinical-stage biotechnology company, announced the appointment of John Harlow as President and Chief Operating Officer, effective September 29, 2026. He will report to Carole Ben-Maimon, Larimar's Chief Executive Officer.

(RTTNews) - Mayne Pharma Group Limited (MYX.AX) has reached settlement with Sun Pharmaceutical Industries Ltd. (SUNPHARMA.NS), resolving the Paragraph 1V patent litigation concerning IMVEXXY (estradiol vaginal inserts) and its U.S. FDA Orange Book-listed patents.

(RTTNews) - Eli Lilly and Company (LLY) announced detailed results from the Phase 3 TRIUMPH-2 study showing that retatrutide delivered substantial weight loss and blood sugar improvements in adults living with obesity or overweight and type 2 diabetes.